胸部肿瘤术后早期应用低分子肝素预防肺栓塞的临床研究(1)
【摘要】 目的：探討胸部肿瘤术后早期应用低分子肝素预防肺栓塞的临床价值。方法：回顾性分析2015年1月-2017年6月在广东省汕头市潮阳区大峰医院胸外科和广东医科大学附属医院心胸外科住院行胸部肿瘤根治外科手术的186例患者的临床资料，并根据其术后早期是否应用低分子肝素分为无肝素组(n=98)与有肝素组(n=88)。比较两组患者治疗前后动脉血气分析以及术前和术后第2、6天的
D-二聚体(D-D)和凝血酶原时间(PT)。并对所有患者随访资料进行分析，比较两组患者术后肺栓塞以及不良反应发生风险。结果：有肝素组患者术后第2、6天的D-D、PT均明显低于无肝素组(P<0.05)；有肝素组患者治疗后PaO2明显高于无肝素组(P<0.05)，而PA-aO2明显低于无肝素组(P<0.05)；有肝素组患者胸部肿瘤术后肺栓塞发生率为2.27%(2/88)，明显低于无肝素组的11.22%(11/98)(字2=5.715，P=0.017)；两组患者不良反应发生率比较，差异无统计学意义(P>0.05)。结论：胸部肿瘤术后早期应用低分子肝素可有效预防患者术后肺栓塞发生风险，且不增加术后出血风险。
, 百拇医药
【关键词】 胸部肿瘤； 肺栓塞； 低分子肝素； 预防
Clinical Analysis of Early Application of Low Molecular Weight Heparin for Prevention of Pulmonary Embolism after Chest Tumor Surgery/ZHENG Yanhong，CHEN Shaopeng，XIAO Huihai，et al.//Medical Innovation of China，2018，15(23)：0-069
【Abstract】 Objective：To evaluate the clinical value of early application of low molecular weight heparin in the prevention of pulmonary embolism after chest tumor surgery.Method：The clinical data of 186 patients undergoing radical thoracic surgery from January 2015 to June 2017 in the Thoracic Surgery Department of Dafeng Hospital and Cardiothoracic Surgery Department of Affiliated Hospital of GDMU were retrospectively analyzed.According to whether or not low molecular weight heparin was used in early postoperative period，patients were divided into non-heparin group(n=98) and heparin group(n=88).Arterial blood gas analysis，D-dimer and prothrombin time before and after treatment were compared between the two groups.All the patients were followed up and the risk of postoperative pulmonary embolism and adverse reactions was compared between the two groups.Result：D-D and PT in the heparin group were significantly lower than those in the non-heparin group on the 2nd and 6th postoperative days(P<0.05).PaO2 in the heparin group was significantly higher than that in the non-heparin group(P<0.05)；PA-aO2 in the heparin group was significantly lower than that in the non-heparin group(P<0.05)；the incidence of pulmonary embolism after chest tumor in heparin group was 2.27%(2/88)，which was significantly lower than 11.22%(11/98) in the non-heparin group(字2=5.715，P=0.017).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion：Early application of low molecular weight heparin in thoracic tumors can effectively prevent the risk of postoperative pulmonary embolism and does not increase the risk of postoperative bleeding.
【Key words】 Thoracic neoplasms； Pulmonary embolism； Low molecular weight heparin； Prevention, http://www.100md.com(郑衍洪 陈少蓬 肖辉海)
D-二聚体(D-D)和凝血酶原时间(PT)。并对所有患者随访资料进行分析，比较两组患者术后肺栓塞以及不良反应发生风险。结果：有肝素组患者术后第2、6天的D-D、PT均明显低于无肝素组(P<0.05)；有肝素组患者治疗后PaO2明显高于无肝素组(P<0.05)，而PA-aO2明显低于无肝素组(P<0.05)；有肝素组患者胸部肿瘤术后肺栓塞发生率为2.27%(2/88)，明显低于无肝素组的11.22%(11/98)(字2=5.715，P=0.017)；两组患者不良反应发生率比较，差异无统计学意义(P>0.05)。结论：胸部肿瘤术后早期应用低分子肝素可有效预防患者术后肺栓塞发生风险，且不增加术后出血风险。
, 百拇医药
【关键词】 胸部肿瘤； 肺栓塞； 低分子肝素； 预防
Clinical Analysis of Early Application of Low Molecular Weight Heparin for Prevention of Pulmonary Embolism after Chest Tumor Surgery/ZHENG Yanhong，CHEN Shaopeng，XIAO Huihai，et al.//Medical Innovation of China，2018，15(23)：0-069
【Abstract】 Objective：To evaluate the clinical value of early application of low molecular weight heparin in the prevention of pulmonary embolism after chest tumor surgery.Method：The clinical data of 186 patients undergoing radical thoracic surgery from January 2015 to June 2017 in the Thoracic Surgery Department of Dafeng Hospital and Cardiothoracic Surgery Department of Affiliated Hospital of GDMU were retrospectively analyzed.According to whether or not low molecular weight heparin was used in early postoperative period，patients were divided into non-heparin group(n=98) and heparin group(n=88).Arterial blood gas analysis，D-dimer and prothrombin time before and after treatment were compared between the two groups.All the patients were followed up and the risk of postoperative pulmonary embolism and adverse reactions was compared between the two groups.Result：D-D and PT in the heparin group were significantly lower than those in the non-heparin group on the 2nd and 6th postoperative days(P<0.05).PaO2 in the heparin group was significantly higher than that in the non-heparin group(P<0.05)；PA-aO2 in the heparin group was significantly lower than that in the non-heparin group(P<0.05)；the incidence of pulmonary embolism after chest tumor in heparin group was 2.27%(2/88)，which was significantly lower than 11.22%(11/98) in the non-heparin group(字2=5.715，P=0.017).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion：Early application of low molecular weight heparin in thoracic tumors can effectively prevent the risk of postoperative pulmonary embolism and does not increase the risk of postoperative bleeding.
【Key words】 Thoracic neoplasms； Pulmonary embolism； Low molecular weight heparin； Prevention, http://www.100md.com(郑衍洪 陈少蓬 肖辉海)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺循环疾病 > 肺栓塞